742 related articles for article (PubMed ID: 16924943)
1. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
van Leth F; Lange JM
Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
[TBL] [Abstract][Full Text] [Related]
2. [Efavirenz--comprehensive status of studies].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
[No Abstract] [Full Text] [Related]
3. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
4. Non-nucleoside reverse transcriptase inhibitors--an overview.
Bell C; Matthews GV; Nelson MR
Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
[No Abstract] [Full Text] [Related]
5. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
Torre D; Tambini R; Speranza F
HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
[TBL] [Abstract][Full Text] [Related]
6. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
[No Abstract] [Full Text] [Related]
7. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
[TBL] [Abstract][Full Text] [Related]
8. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
Manfredi R; Calza L; Chiodo F
J Acquir Immune Defic Syndr; 2004 Apr; 35(5):492-502. PubMed ID: 15021314
[TBL] [Abstract][Full Text] [Related]
10. HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
Meyer-Kleinmann J
Infection; 2004 Jun; 32(3):7. PubMed ID: 15230276
[No Abstract] [Full Text] [Related]
11. NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F; Torralba M
J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
[No Abstract] [Full Text] [Related]
12. The role of NNRTIs in antiretroviral combination therapy: an introduction.
Nelson M
Int J STD AIDS; 2001 Nov; 12 Suppl 4():1-2. PubMed ID: 11589821
[TBL] [Abstract][Full Text] [Related]
13. Efavirenz: resistance and cross-resistance.
Clotet B
Int J Clin Pract Suppl; 1999 Jun; 103():21-5. PubMed ID: 10622039
[TBL] [Abstract][Full Text] [Related]
14. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
Manfredi R; Calza L; Chiodo F
HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
[TBL] [Abstract][Full Text] [Related]
15. NNRTIs: a neglected class.
Cadman J
GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
[TBL] [Abstract][Full Text] [Related]
16. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Kontorinis N; Dieterich DT
Semin Liver Dis; 2003 May; 23(2):173-82. PubMed ID: 12800070
[TBL] [Abstract][Full Text] [Related]
18. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
[TBL] [Abstract][Full Text] [Related]
19. The tolerability of efavirenz after nevirapine-related adverse events.
Clarke S; Harrington P; Barry M; Mulcahy F
Clin Infect Dis; 2000 Sep; 31(3):806-7. PubMed ID: 11017835
[TBL] [Abstract][Full Text] [Related]
20. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
